Skip to main content
. 2025 Sep 3;29(3):e2025.00048. doi: 10.4293/JSLS.2025.00048

Table 1.

Demographic and Follow-up Data of the Groups

Overall (N = 255) (Mean ± SD) Group 1(N = 220) (Mean ± SD) Group 2(N = 35) (Mean ± SD) P-Value
Age (years) 65.18 ± 6.51 (45–80) 65.32 ± 6.11 (45–78) 67.14 ± 5.71 (55–80) .134
BMI2 (kg/m²) 25.32 ± 3.02 (18–34) 25.36 ± 2.99 (19–34) 25.11 ± 3.22 (18–31) .661
Prostate volume (mL) 52.40 ± 24.09 (18–220) 52.57 ± 25.09 (18–220) 51.35 ± 16.47 (25–85) .785
Preoperative T PSA (ng/mL) 10.22 ± 7.51 (2.12–68) 11.07 ± 4.28 (2.12–33.3) 13.19 ± 10.44 (4.72–68) .078
Operative time (minutes) 179.35 ± 32.33 (50–260) 176.87 ± 32.05 (50–250) 194.86 ± 30.4 (140–260) .002
Postoperative 3-month PSA 0.12 ± 0.02 (0.00–1.69) 0.11 ± 0.39 (0.00–1.69) 0.09 ± 0.41 (0.01–0.81) .067
Blood loss (mL) 178.90 ± 101.8 (50–600) 175.14 ± 98.17 (50–500) 159.86 ± 102.6 (50–600) .054
Drain duration (days) 4.37 ± 0.93 (2–6) 4.38 ± 0.94 (2–6) 4.29 ± 0.86 (3–6) .581
Hospital stay (days) 6.67 ± 1.71 (4–10) 6.62 ± 1.69 (4–10) 6.94 ± 1.80 (4–10) .302
Catheter duration (days) 11.22 ± 2.27 (7–14) 11.17 ± 2.31 (7–14) 11.69 ± 1.98 (7–14) .217
VAS 5.91 ± 1.23 (0–8) 5.94 ± 1.22 (0–8) 5.74 ± 1.31 (3–8) .311

Group 1: ELRP in patients without a history of IHR; group 2: ELRP in patients with a history of IHR; SD, standard deviation; BMI, body mass index; PSA, prostate-specific antigen; VAS, visual analog scale.